NCT03460977 2026-03-13
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Phase 1 Recruiting
Pfizer
Amgen
University of Oklahoma
University of Chicago
Alessa Therapeutics Inc.
Vir Biotechnology, Inc.